Read the latest cancer news from the National Cancer Institute. The UNM Comprehensive Cancer Center is one of only 49 NCI-designated comprehensive cancer centers bringing leading, national cancer care to New Mexico.
Brain cells called astrocytes can activate PPAR-gamma, a growth protein in cancer cells that helps them gain a foothold in the brain, a new study shows. The findings suggest that drugs that block PPAR-gamma activity may help treat brain metastases.
Scientists may have pinpointed the cause of some gastrointestinal stromal tumors (GISTs), a rare cancer, according to a new NCI-funded study. However, the culprit isn’t a harmful genetic mutation, but another type of genetic change, what are called epigenetic alterations.
For people with colorectal cancer with a specific mutation in the BRAF gene, a treatment regimen of three targeted drugs can improve how long they live without increasing their risk of serious side effects, results from a new clinical trial show.
Updated guidelines on exercise in those living with cancer and cancer survivors were recently released. In this conversation, Dr. Kathryn Schmitz discusses what these new guidelines mean for doctors, patients, and survivors.
A large clinical trial showed that adding the immunotherapy drug durvalumab (Imfinzi) to standard chemotherapy can prolong survival in some people with previously untreated advanced small cell lung cancer.
In three large clinical trials of women with newly diagnosed ovarian cancer, treatment with a PARP inhibitor as first-line therapy, maintenance therapy, or both, extended the length of time before participants’ cancers came back or got worse.
Results from a new study suggest a potential way to improve the effectiveness of CAR T-cell therapy for multiple myeloma. The approach relies on a class of drugs called gamma-secretase inhibitors (GSIs), several of which have been studied to treat Alzheimer’s disease.
A TAILORx analysis shows women with early-stage breast cancer and high recurrence scores on the Oncotype DX who received chemotherapy with hormone therapy had better long-term outcomes than what would be expected from hormone therapy alone.
Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.